Scroll

thioridazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2637	50-52-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: thioridazine thioridazin dl-Thioridazine malloryl meleril thioridazine hydrochloride thioridazine HCl	A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA. Molecular weight: 370.57 Formula: C21H26N2S2 CLOGP: 6.20 LIPINSKI: 1 HAC: 2 HDO: 0 TPSA: 6.48 ALOGS: -5.64 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

thioridazine
thioridazin
dl-Thioridazine
malloryl
meleril
thioridazine hydrochloride
thioridazine HCl

A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.

Molecular weight: 370.57
Formula: C21H26N2S2
CLOGP: 6.20
LIPINSKI: 1
HAC: 2
HDO: 0
TPSA: 6.48
ALOGS: -5.64
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.30	g	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	40 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
MRTD (Maximum Recommended Therapeutic Daily Dose)	35.89 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Bocci G, Oprea TI, Benet LZ
S (Water solubility)	0.00 mg/mL	Bocci G, Oprea TI, Benet LZ

Showing 1 to 4 of 4 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
March 15, 1962	FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Antipsychotic drug level below therapeutic	505.88	188.88	90	1603	2457	34952781
Therapeutic product effect variable	489.15	188.88	87	1606	2369	34952869
Disinhibition	484.64	188.88	90	1603	3136	34952102
Obsessive-compulsive disorder	471.09	188.88	96	1597	5468	34949770
Euphoric mood	434.46	188.88	90	1603	5551	34949687
Increased appetite	409.76	188.88	90	1603	7339	34947899
Akathisia	401.91	188.88	90	1603	8019	34947219
Suicide attempt	265.63	188.88	91	1602	39025	34916213
Therapeutic product effect incomplete	228.25	188.88	87	1606	50454	34904784
Leukopenia	203.07	188.88	85	1608	62771	34892467

Showing 1 to 10 of 11 entries

Previous1 2Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Antipsychotic drug level below therapeutic	157.03	56.36	25	1097	1213	79742053
Therapeutic product effect variable	144.93	56.36	25	1097	1984	79741282
Disinhibition	138.51	56.36	25	1097	2573	79740693
Obsessive-compulsive disorder	117.94	56.36	25	1097	5902	79737364
Euphoric mood	111.34	56.36	25	1097	7701	79735565
Akathisia	107.83	56.36	27	1095	13232	79730034
Dyslipidaemia	101.16	56.36	25	1097	11608	79731658
Increased appetite	100.43	56.36	25	1097	11953	79731313
Obesity	77.82	56.36	26	1096	35099	79708167
Irritability	62.49	56.36	23	1099	41121	79702145

Showing 1 to 10 of 12 entries

Previous1 2Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	N05AC02	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Phenothiazines with piperidine structure
CHEBI has role	CHEBI:37890	alpha-adrenergic receptor blockaders
CHEBI has role	CHEBI:37955	H1 receptor antagonists
CHEBI has role	CHEBI:48279	serotonin antagonists
CHEBI has role	CHEBI:48561	dopaminergic antagonists
CHEBI has role	CHEBI:65190	typical antipsychotic drugs
CHEBI has role	CHEBI:76779	post-proline endopeptidase inhibitors
CHEBI has role	CHEBI:77402	EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitors
CHEBI has role	CHEBI:176497	geroprotectors
FDA CS	M0016525	Phenothiazines

Showing 1 to 10 of 19 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Treatment-Resistant Schizophrenia	indication
Hyperkalemia	contraindication	14140009
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Senile dementia	contraindication	15662003
Orthostatic hypotension	contraindication	28651003
Hypokalemia	contraindication	43339004
Epilepsy	contraindication	84757009	DOID:1826
Stupor	contraindication	89458003
Tardive dyskinesia	contraindication	102449007
Prolonged QT interval	contraindication	111975006

Showing 1 to 10 of 15 entries

Previous1 2Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.22	Basic
pKa2	3.45	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST	IC50	7.40	WOMBAT-PK	CHEMBL
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		IC50	7.10	WOMBAT-PK
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.87	PDSP
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	6.82	DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	7	WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	5.90	PDSP
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.81	DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN	ANTAGONIST	Ki	7.10	IUPHAR
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN	ANTAGONIST	EC50	8	WOMBAT-PK
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.09	DRUG MATRIX

Showing 1 to 10 of 61 entries

Previous1 2 3 4 5 6 7Next

External reference:

Show entries

Search:

ID	Source
LZU	PDB_CHEM_ID
001482	NDDF
004591	NDDF
100	IUPHAR_LIGAND_ID
10502	RXNORM
130-61-0	SECONDARY_CAS_RN
1788	MMSL
18550006	SNOMEDCT_US
2125	MMSL
33588000	SNOMEDCT_US

Showing 1 to 10 of 28 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Thioridazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0612	TABLET, FILM COATED	10 mg	ORAL	ANDA	18 sections
Thioridazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0614	TABLET, FILM COATED	25 mg	ORAL	ANDA	18 sections
Thioridazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0616	TABLET, FILM COATED	50 mg	ORAL	ANDA	18 sections
Thioridazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0618	TABLET, FILM COATED	100 mg	ORAL	ANDA	18 sections
Thioridazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	51079-565	TABLET, FILM COATED	10 mg	ORAL	ANDA	18 sections
Thioridazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	51079-566	TABLET, FILM COATED	25 mg	ORAL	ANDA	18 sections
Thioridazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	51079-567	TABLET, FILM COATED	50 mg	ORAL	ANDA	18 sections
Thioridazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	51079-580	TABLET, FILM COATED	100 mg	ORAL	ANDA	18 sections
Thioridazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	53489-148	TABLET, FILM COATED	10 mg	ORAL	ANDA	18 sections
Thioridazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	53489-149	TABLET, FILM COATED	25 mg	ORAL	ANDA	18 sections

Showing 1 to 10 of 13 entries

Previous1 2Next